Selumetinib
| CAS No. | 606143-52-6 |
|---|---|
| MDL No. | MFCD11977472 |
| MF | C17H15BrClFN4O3 |
| MW | 457.70 |
| InChI Key | CYOHGALHFOKKQC-UHFFFAOYSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Selumetinib is a benzimidazole derivative with a 1-methyl-1H-benzimidazole core substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1/MEK2 inhibitor and functions as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor, antineoplastic agent, and anticoronaviral agent. It belongs to the classes of benzimidazoles, hydroxamic acid esters, monochlorobenzenes, bromobenzenes, organofluorine compounds, and secondary amino compounds.
| CAS No. | 606143-52-6 |
|---|---|
| Product Name | Selumetinib |
Biological Targets
MAP2K1·MAP2K2
Associated Conditions
iris melanoma·astrocytoma·ovarian carcinoma·biliary tract cancer·thyroid carcinoma·
* The information provided here is compiled from public sources and is for reference only.
